Stocks were flat to start the day as investors awaited the Fed’s latest interest rate decision and near-term projections for the U.S. economy later today. Federal Reserve policymakers are widely expected to hike interest rates by an additional 50 basis points in their ongoing effort to tamp high inflation.
Value-oriented shares have been performing well recently and have been supported by gains in the consumer staples sector. There are a multitude of experts proclaiming that value stocks will be en vogue in 2023 – and indeed, many have already started to rally in 2022’s late innings.
Today’s recommendation is a company from a defensive industry with a reputation for being resilient during times of economic weakness that’s currently trading at a discount and seems to be gaining traction as investors focus more on finding value.
A Return to Normal? PhD Economist: “Don’t Bet on It”
According to former Goldman Sachs executive, Nomi Prins…
Americans who are hoping for a ‘return to normal’ are going to be shocked when they see what happens next in America.
She says, “If you’re betting your job, savings, or retirement accounts on a return to ‘normal’ you’re about to be left behind by a brand-new crisis few see coming.”
Go here now to see America’s next crisis
Trusted neighborhood pharmacy Walgreens Boots Alliance (WBA) has always been a popular place for consumers, but like many consumer-driven businesses, Walgreens has been under pressure in 2022. As both a healthcare play and a consumer staples retailer, WBA is known for remarkable stability throughout the years both in terms of margins and revenue, making it an attractive option for anyone seeking dependable value.
Last year, the company’s $5.2 billion investment in primary-care business VillageMD set the stage for the launch of doctor’s offices at hundreds of Walgreens locations across the country. While management cautioned that it could take two years for the partnership to scale to “a reasonable level of operations” for patient investors, the collaboration will likely provide solid growth opportunities for the business. Walgreens management sees 1,000 co-located clinics across more than 30 markets by 2027.
Despite rallying 30% since October, WBA is still trading at a significant discount compared to peers. WBA is valued at around 23% of total sales, compared to top competitor CVS Health (CVS), which is currently valued at about 40% of total sales. CVS currently trades at nearly 12 times forward earnings, while WBA trades at less than 7.5 times earnings. The stock also boasts an impressive 4.6% and is still down 23% this year, but could continue to build on recent momentum as investors turn their focus towards value.